Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Cutaneous or Indolent Systemic Mastocytosis: Proof-of-Concept
2020-003268-25Phase 2Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Change in mast cell activation symptoms (pruritus and/or flushes). Started Aug 2020; status: active.
02
Drugs
hydroxychloroquine
03
Conditions
cutaneous mastocytosis (CM)indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on 2020-003268-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003268-25.